{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,18]],"date-time":"2026-04-18T01:51:53Z","timestamp":1776477113527,"version":"3.51.2"},"reference-count":28,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2012,1,1]],"date-time":"2012-01-01T00:00:00Z","timestamp":1325376000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2012,1,1]],"date-time":"2012-01-01T00:00:00Z","timestamp":1325376000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal Fran\u00e7ais d'Ophtalmologie"],"published-print":{"date-parts":[[2012,1]]},"DOI":"10.1016\/j.jfo.2011.03.012","type":"journal-article","created":{"date-parts":[[2011,10,17]],"date-time":"2011-10-17T01:24:35Z","timestamp":1318814675000},"page":"9-16","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":7,"title":["Plasma levels and systemic safety of 0.1% unpreserved Timolol maleate gel, 0.5% Timolol aqueous solution and 0.5% Timolol maleate gel"],"prefix":"10.1016","volume":"35","author":[{"given":"N.","family":"Bonnin","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"H.","family":"Nezzar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C.","family":"Dubray","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"D.","family":"Renault","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C.","family":"Olmiere","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"F.","family":"Chiambaretta","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.jfo.2011.03.012_bib0005","doi-asserted-by":"crossref","first-page":"1133","DOI":"10.1038\/sj.eye.6701973","article-title":"The impact of Vision 2020 on global blindness","volume":"19","author":"Foster","year":"2005","journal-title":"Eye"},{"key":"10.1016\/j.jfo.2011.03.012_bib0010","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1136\/bjo.2005.081224","article-title":"The number of people with glaucoma worldwide in 2010 and 2020","volume":"90","author":"Quigley","year":"2006","journal-title":"Br J Ophthalmol"},{"key":"10.1016\/j.jfo.2011.03.012_bib0015","doi-asserted-by":"crossref","first-page":"208","DOI":"10.2165\/00002512-199202030-00005","article-title":"Ocular beta-blockers in glaucoma management. Clinical pharmacological aspects","volume":"2","author":"Brooks","year":"1992","journal-title":"Drugs Aging"},{"key":"10.1016\/j.jfo.2011.03.012_bib0020","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1016\/S0002-9394(14)76213-0","article-title":"Evaluation of once-daily levobunolol 0.25% and timolol 0.25% therapy for increased intraocular pressure","volume":"112","author":"Silverstone","year":"1991","journal-title":"Am J Ophthalmol"},{"key":"10.1016\/j.jfo.2011.03.012_bib0025","doi-asserted-by":"crossref","first-page":"120","DOI":"10.7326\/0003-4819-112-2-120","article-title":"Systemic effects of medications used to treat glaucoma","volume":"112","author":"Everitt","year":"1990","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.jfo.2011.03.012_bib0030","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1097\/00132580-200111000-00007","article-title":"Cardiovascular considerations in using topical, oral, and intravenous drugs for the treatment of glaucoma and ocular hypertension: focus on beta-adrenergic blockade","volume":"3","author":"Frishman","year":"2001","journal-title":"Heart Dis"},{"key":"10.1016\/j.jfo.2011.03.012_bib0035","doi-asserted-by":"crossref","first-page":"606","DOI":"10.1016\/0002-9394(86)90532-5","article-title":"Adverse respiratory and cardiovascular events attributed to timolol ophthalmic solution, 1978\u20131985","volume":"102","author":"Nelson","year":"1986","journal-title":"Am J Ophthalmol"},{"key":"10.1016\/j.jfo.2011.03.012_bib0040","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1111\/j.1524-6175.2001.00466.x","article-title":"Current concepts of pharmacotherapy in hypertension\u00a0\u2013\u00a0ophthalmically administered beta-blockers and their cardiopulmonary effects","volume":"3","author":"Sica","year":"2001","journal-title":"J Clin Hypertens (Greenwich)"},{"key":"10.1016\/j.jfo.2011.03.012_bib0045","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1001\/archinte.158.3.221","article-title":"Beta-blocker-induced complications and the patient with glaucoma. Newer treatments to help reduce systemic adverse events","volume":"158","author":"Stewart","year":"1998","journal-title":"Arch Intern Med"},{"key":"10.1016\/j.jfo.2011.03.012_bib0050","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1016\/0002-9394(85)90227-2","article-title":"Cardiovascular effects of topical beta-blockers during exercise","volume":"99","author":"Atkins","year":"1985","journal-title":"Am J Ophthalmol"},{"key":"10.1016\/j.jfo.2011.03.012_bib0055","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1111\/j.1755-3768.1988.tb04041.x","article-title":"Comparison of topical timolol vs betaxolol on cardiopulmonary exercise performance in healthy volunteers","volume":"66","author":"Dickstein","year":"1988","journal-title":"Acta Ophthalmol (Copenh)"},{"key":"10.1016\/j.jfo.2011.03.012_bib0060","doi-asserted-by":"crossref","first-page":"1517","DOI":"10.1001\/archopht.1984.01040031237026","article-title":"Effect of topical timolol maleate on exercise performance","volume":"102","author":"Doyle","year":"1984","journal-title":"Arch Ophthalmol"},{"key":"10.1016\/j.jfo.2011.03.012_bib0065","doi-asserted-by":"crossref","first-page":"1441","DOI":"10.1056\/NEJM198411293112213","article-title":"Respiratory effects of timolol","volume":"311","author":"Fraunfelder","year":"1984","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jfo.2011.03.012_bib0070","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1016\/S0002-9394(99)00160-9","article-title":"Beta-blocker eye drops nocturnal arterial hypotension","volume":"128","author":"Hayreh","year":"1999","journal-title":"Am J Ophthalmol"},{"key":"10.1016\/j.jfo.2011.03.012_bib0075","doi-asserted-by":"crossref","first-page":"197","DOI":"10.7326\/0003-4819-104-2-197","article-title":"Cardiovascular effects of ophthalmic timolol","volume":"104","author":"Leier","year":"1986","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.jfo.2011.03.012_bib0080","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1016\/S0167-5273(01)00489-2","article-title":"Third degree AC block due to ophthalmic timolol solution","volume":"80","author":"Sharifi","year":"2001","journal-title":"Int J Cardiol"},{"key":"10.1016\/j.jfo.2011.03.012_bib0085","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1007\/s00417-002-0462-2","article-title":"Systemic bioavailability and cardiopulmonary effects of 0.5% timolol eyedrops","volume":"240","author":"Korte","year":"2002","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"10.1016\/j.jfo.2011.03.012_bib0090","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1016\/0378-5173(90)90214-O","article-title":"Controlled drug delivery devices for experimental ocular studies with timolol 1. In vitro release studies","volume":"61","author":"Urtti","year":"1990","journal-title":"Int J Pharm"},{"key":"10.1016\/j.jfo.2011.03.012_bib0095","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1159\/000067548","article-title":"Timolol 0.1% gel (nyogel 0.1% once daily versus conventional timolol 0.5% solution twice daily: a comparison of efficacy and safety","volume":"216","author":"Rouland","year":"2002","journal-title":"Ophthalmologica"},{"key":"10.1016\/j.jfo.2011.03.012_bib0100","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1111\/j.1600-0420.2005.00562.x","article-title":"Efficacy and systemic side effects of topical 0.5% timolol aqueous solution and 0.1% timolol hydrogel","volume":"83","author":"Uusitalo","year":"2005","journal-title":"Acta Ophthalmol Scand"},{"key":"10.1016\/j.jfo.2011.03.012_bib0105","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1016\/S0002-9394(14)70432-5","article-title":"Comparison of the effects of aqueous and gellan ophthalmic timolol on peak exercise performance in middle-aged men","volume":"121","author":"Dickstein","year":"1996","journal-title":"Am J Ophthalmol"},{"key":"10.1016\/j.jfo.2011.03.012_bib0110","doi-asserted-by":"crossref","first-page":"626","DOI":"10.1016\/S0002-9394(01)01181-3","article-title":"Comparison of aqueous and gellan ophthalmic timolol with placebo on the 24-hour heart rate response in patients on treatment for glaucoma","volume":"132","author":"Dickstein","year":"2001","journal-title":"Am J Ophthalmol"},{"key":"10.1016\/j.jfo.2011.03.012_bib0115","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1016\/S0149-2918(01)80048-5","article-title":"Efficacy and tolerability of timolol maleate ophthalmic gel-forming solution versus timolol ophthalmic solution in adults with open-angle glaucoma or ocular hypertension: a six-month, double-masked, multicenter study","volume":"23","author":"Shedden","year":"2001","journal-title":"Clin Ther"},{"key":"10.1016\/j.jfo.2011.03.012_bib0120","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1097\/00061198-200106000-00015","article-title":"Effect of timolol 0.5% gel and solution on pulmonary function in older glaucoma patients","volume":"10","author":"Stewart","year":"2001","journal-title":"J Glaucoma"},{"key":"10.1016\/j.jfo.2011.03.012_bib0125","first-page":"692","article-title":"Should beta-blockers be abandoned as initial monotherapy in chronic open angle glaucoma? View 1","volume":"86","author":"Anton","year":"2002","journal-title":"Br J Ophthalmol"},{"key":"10.1016\/j.jfo.2011.03.012_bib0130","doi-asserted-by":"crossref","first-page":"574","DOI":"10.1136\/bjo.2005.080424","article-title":"Comparison of a non-preserved 0.1% T-Gel eye gel (single-dose unit) with a preserved 0.1% T-Gel eye gel (multidose) in ocular hypertension and glaucomatous patients","volume":"90","author":"Easty","year":"2006","journal-title":"Br J Ophthalmol"},{"key":"10.1016\/j.jfo.2011.03.012_bib0135","doi-asserted-by":"crossref","first-page":"1491","DOI":"10.1007\/s00417-006-0328-0","article-title":"Improved systemic safety and risk-benefit ratio of topical 0.1% timolol hydrogel compared with 0.5% timolol aqueous solution in the treatment of glaucoma","volume":"244","author":"Uusitalo","year":"2006","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"10.1016\/j.jfo.2011.03.012_bib0140","doi-asserted-by":"crossref","first-page":"1102","DOI":"10.1076\/ceyr.16.11.1102.5101","article-title":"Effect of topical beta-blockers on tissue blood flow in the human optic nerve head","volume":"16","author":"Tamaki","year":"1997","journal-title":"Curr Eye Res"}],"container-title":["Journal Fran\u00e7ais d'Ophtalmologie"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0181551211002026?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0181551211002026?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,30]],"date-time":"2025-09-30T19:03:15Z","timestamp":1759258995000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0181551211002026"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,1]]},"references-count":28,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2012,1]]}},"alternative-id":["S0181551211002026"],"URL":"https:\/\/doi.org\/10.1016\/j.jfo.2011.03.012","relation":{},"ISSN":["0181-5512"],"issn-type":[{"value":"0181-5512","type":"print"}],"subject":[],"published":{"date-parts":[[2012,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Plasma levels and systemic safety of 0.1% unpreserved Timolol maleate gel, 0.5% Timolol aqueous solution and 0.5% Timolol maleate gel","name":"articletitle","label":"Article Title"},{"value":"Journal Fran\u00e7ais d'Ophtalmologie","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jfo.2011.03.012","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2011 Published by Elsevier Masson SAS","name":"copyright","label":"Copyright"}]}}